Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT.
The webinar, hosted by the Praxis management team, will focus on the company’s clinical programs in developmental and epileptic encephalopathies (DEEs) including:
- The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs
- The EMERALD study evaluating relutrigine for broader DEEs
- The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE
To RSVP and attend the live event, you may click . A replay of the webinar will also be available through the “” page under the “” section of the company’s website for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on , , and .
Investor Contact: Praxis Precision Medicines 857-702-9452 Media Contact: Dan Ferry Life Science Advisors 617-430-7576
